CTLA4 and neoplasm: When α-PD-1 was added to α-CTLA-4 blockade as in the combination group, ‘escape' of tumour from α-CTLA-4 monotherapy was blocked and all tumours were rejected, providing direct evidence that MB49 tumours utilize the PD-1 pathway to evade α-CTLA-4 monotherapy.